FDG-PET/CT in high-risk primary breast cancer-a prospective study of stage migration and clinical impact.
Breast cancer
Clinical impact
FDG-PET/CT
Incidental findings
Stage migration
Journal
Breast cancer research and treatment
ISSN: 1573-7217
Titre abrégé: Breast Cancer Res Treat
Pays: Netherlands
ID NLM: 8111104
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
received:
02
07
2020
accepted:
04
09
2020
pubmed:
14
9
2020
medline:
24
6
2021
entrez:
13
9
2020
Statut:
ppublish
Résumé
To investigate the clinical impact of FDG-PET/CT for staging and treatment planning in high-risk primary breast cancer. Women with high-risk primary breast cancer were enrolled between September 2017 and August 2019 at Odense University Hospital, Denmark. Conventional mammography with/without MRI was performed before staging by FDG-PET/CT. We studied the accuracy of FDG-PET/CT for the detection of distant metastases, the effect on the change of treatment, and the prevalence of incidental findings. Biopsy and follow-up were used as a reference standard for the accuracy analysis. Of 103 women, 24 (23%) were diagnosed with distant metastases by FDG-PET/CT. Among these, breast surgery was omitted in 18 and could have been spared in six. Another sixteen (16%) patients were upstaged to more advanced loco-regional disease, leading to more extensive radiotherapy. Sensitivity and specificity for diagnosing distant metastases were 1.00 (95% confidence interval: 0.86-1.00) and 0.95 (0.88-0.99), respectively. Twenty-nine incidental findings were detected in 24 women (23%), leading to further examinations in 22 and diagnosis of eight (8/22, 36%) synchronous diseases: cancer (n = 4), thyroiditis (n = 2), aorta aneurysm (n = 1), and meningioma (n = 1). FDG-PET/CT had a substantial impact on staging and change of treatment in women with high-risk primary breast cancer, and further examination of incidental findings was considered clinically relevant. Our findings suggest that FDG-PET/CT should be considered for primary staging in high-risk primary breast cancer to improve treatment planning.
Identifiants
pubmed: 32920740
doi: 10.1007/s10549-020-05929-3
pii: 10.1007/s10549-020-05929-3
doi:
Substances chimiques
Radiopharmaceuticals
0
Fluorodeoxyglucose F18
0Z5B2CJX4D
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
145-153Subventions
Organisme : Det Frie Forskningsråd
ID : DFF - 7016-00359
Références
Hortobagyi GN, Connolly JL, D'orsi CJ, Edge SB, Mittendorf EA, Rugo HS, Solin LJ, Weaver DL, Winchester DJ, Giuliano AE (2018) AJCC Cancer Staging Manual 8th, Breast, Part XI. In., 8 edn.,
Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio IT, Zackrisson S, Senkus E, Committee EG (2019) Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Annals Oncol 30(8):1194–1220. https://doi.org/10.1093/annonc/mdz173
doi: 10.1093/annonc/mdz173
NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf . Accessed Apr 8 2020
Koolen BB, Vrancken Peeters M-JTFD, Aukema TS, Vogel WV, Oldenburg HSA, van der Hage JA, Hoefnagel CA, Stokkel MPM, Loo CE, Rodenhuis S, Rutgers EJT, Valdés Olmos RA (2012) 18F-FDG PET/CT as a staging procedure in primary stage II and III breast cancer: comparison with conventional imaging techniques. Breast Cancer Res Treat 131(1):117–126. https://doi.org/10.1007/s10549-011-1767-9
doi: 10.1007/s10549-011-1767-9
pubmed: 21935602
Caresia Aroztegui AP, Garcia Vicente AM, Alvarez Ruiz S, Delgado Bolton RC, Orcajo Rincon J, Garcia Garzon JR, de Arcocha TM, Garcia-Velloso MJ (2017) 18F-FDG PET/CT in breast cancer: Evidence-based recommendations in initial staging. Tumour Biol 39(10):1010428317728285. https://doi.org/10.1177/1010428317728285
doi: 10.1177/1010428317728285
pubmed: 29025377
Groheux D (2017) FDG-PET/CT for systemic staging of patients with newly diagnosed breast cancer. Eu J Nuclear Med Mol Imaging 44(9):1417–1419. https://doi.org/10.1007/s00259-017-3731-3
doi: 10.1007/s00259-017-3731-3
Ulaner GA (2019) PET/CT for Patients With Breast Cancer: Where Is the Clinical Impact? Am J Roentgenol. https://doi.org/10.2214/ajr.19.21177
doi: 10.2214/ajr.19.21177
Groheux D, Giacchetti S, Delord M, Hindie E, Vercellino L, Cuvier C, Toubert ME, Merlet P, Hennequin C, Espie M (2013) 18F-FDG PET/CT in staging patients with locally advanced or inflammatory breast cancer: comparison to conventional staging. J Nuclear Med 54(1):5–11. https://doi.org/10.2967/jnumed.112.106864
doi: 10.2967/jnumed.112.106864
Garg PK, Deo SVS, Kumar R, Shukla NK, Thulkar S, Gogia A, Sharma DN, Mathur SR (2016) Staging PET-CT Scanning Provides Superior Detection of Lymph Nodes and Distant Metastases than Traditional Imaging in Locally Advanced Breast Cancer. World J Surg 40(8):2036–2042. https://doi.org/10.1007/s00268-016-3570-6
doi: 10.1007/s00268-016-3570-6
pubmed: 27220508
Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig L, Lijmer JG, Moher D, Rennie D, de Vet HC, Kressel HY, Rifai N, Golub RM, Altman DG, Hooft L, Korevaar DA, Cohen JF (2015) STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies. BMJ (Clinical research ed) 351:h5527. https://doi.org/10.1136/bmj.h5527
doi: 10.1136/bmj.h5527
Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ (2011) Strategies for subtypes–dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22(8):1736–1747. https://doi.org/10.1093/annonc/mdr304
doi: 10.1093/annonc/mdr304
pubmed: 21709140
pmcid: 3144634
Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, Verzijlbergen FJ, Barrington SF, Pike LC, Weber WA, Stroobants S, Delbeke D, Donohoe KJ, Holbrook S, Graham MM, Testanera G, Hoekstra OS, Zijlstra J, Visser E, Hoekstra CJ, Pruim J, Willemsen A, Arends B, Kotzerke J, Bockisch A, Beyer T, Chiti A, Krause BJ (2015) FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging 42(2):328–354. https://doi.org/10.1007/s00259-014-2961-x
doi: 10.1007/s00259-014-2961-x
pubmed: 25452219
Groheux D, Hindié E, Delord M, Giacchetti S, Hamy A-s, de Bazelaire C, de Roquancourt A, Vercellino L, Toubert M-E, Merlet P, Espié M (2012) Prognostic impact of (18)FDG-PET-CT findings in clinical stage III and IIB breast cancer. J Natl Cancer Inst 104(24):1879–1887. https://doi.org/10.1093/jnci/djs451
doi: 10.1093/jnci/djs451
pubmed: 23243198
pmcid: 3525816
Feinstein AR, Sosin DM, Wells CK (1985) The Will Rogers phenomenon Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. The New England journal of medicine 312(25):1604–1608. https://doi.org/10.1056/nejm198506203122504
doi: 10.1056/nejm198506203122504
pubmed: 4000199
Sormani MP (2009) The Will Rogers phenomenon: the effect of different diagnostic criteria. J Neurol Sci 287(Suppl 1):S46–49. https://doi.org/10.1016/s0022-510x(09)71300-0
doi: 10.1016/s0022-510x(09)71300-0
pubmed: 20106348
Gajjala SR, Hulikal N, Kadiyala S, Kottu R, Kalawat T (2018) Whole-body (18)F-fluorodeoxyglucose positron emission tomography-computed tomography ((18)F-FDG PET/CT) for staging locally advanced breast cancer: A prospective study from a tertiary cancer centre in south India. Indian J Med Res 147(3):256–262. https://doi.org/10.4103/ijmr.IJMR_1368_16
doi: 10.4103/ijmr.IJMR_1368_16
pubmed: 29923514
pmcid: 6022380
Britt CJ, Maas AM, Kennedy TA, Hartig GK (2018) Incidental Findings on FDG PET/CT in Head and Neck Cancer. Otolaryngol Head Neck Surg 158(3):484–488. https://doi.org/10.1177/0194599817742579
doi: 10.1177/0194599817742579
pubmed: 29160180
Sponholtz SE, Mogensen O, Hildebrandt MG, Jensen PT (2020) Clinical impact of pre-treatment FDG-PET/CT staging of primary ovarian, fallopian tube, and peritoneal cancers in women. Acta Obstet Gynecol Scand 99(2):186–195. https://doi.org/10.1111/aogs.13726
doi: 10.1111/aogs.13726
pubmed: 31505027
Ishimori T, Patel PV, Wahl RL (2005) Detection of unexpected additional primary malignancies with PET/CT. J Nuclear Med 46(5):752–757
Rohde M, Nielsen AL, Johansen J, Sorensen JA, Nguyen N, Diaz A, Nielsen MK, Asmussen JT, Christiansen JM, Gerke O, Thomassen A, Alavi A, Hoilund-Carlsen PF, Godballe C (2017) Head-to-Head Comparison of Chest X-Ray/Head and Neck MRI, Chest CT/Head and Neck MRI, and (18)F-FDG PET/CT for Detection of Distant Metastases and Synchronous Cancer in Oral, Pharyngeal, and Laryngeal Cancer. J Nuclear Med 58(12):1919–1924. https://doi.org/10.2967/jnumed.117.189704
doi: 10.2967/jnumed.117.189704
Kousgaard SJ, Thorlacius-Ussing O (2017) Incidental colorectal FDG uptake on PET/CT scan and lesions observed during subsequent colonoscopy: a systematic review. Tech Coloproctol 21(7):521–529. https://doi.org/10.1007/s10151-017-1652-6
doi: 10.1007/s10151-017-1652-6
pubmed: 28620878
Netherlands I-CCCt Breast cancer guideline, NABON 2012. 2.0